Returning from the afterlife? Sotorasib treatment for advanced KRAS mutant lung cancer: A case report

Figure 1 Pathology of puncture. A: Left lung; B: Pelvic mass.

Figure 2 Treatment flow chart. A: September 2019: Diagnosis with lung cancer and type of gene mutation; B: November 2019: Four cycles of pemetrexed + cisplatin, followed by eight oral tegafur maintenance cycles; C: Adjustment of medication due to myelosuppression; D: Chemotherapy and targeted therapy on 9 February 2022; E: Received immunotherapy on 18 July 2022; F: Metastasis occurred again in February 2023; G: In July 2023, the tumor regressed and the patient improved; H: Sotorasib started on 15 March 2023.

Figure 3 Computed tomography tracking of changes in lung, peritoneal fluid, and pelvic mass before and after treatment with sotorasib. A: Lungs before treatment in the sotorasib group; B: Abdomen before sotorasib treatment; C: Pelvis before sotorasib treatment; D: Lungs after sotorasib treatment; E: Abdomen after sotorasib treatment; F: Pelvis after sotorasib treatment.

Figure 4 Changes in tumor markers. A: Carcinoembryonic antigen (CEA) values; B: Carbohydrate antigen 125 (CA125) values.

Figure 5 Changes in Karnofsky Performance Status score. KPS: Karnofsky Performance Status.